UroGen Pharma

Yahoo Finance • 2 months ago

UroGen Pharma CMO Schoenberg sells $176k in shares

Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd (NASDAQ:URGN), a company with impressive gross margins of 88.5% and a market capitalization of $902 million, sold 10,000 ordinary shares of the company on August 11, 2025. The sha... Full story

Yahoo Finance • 2 months ago

Sector Update: Health Care Stocks Decline Late Afternoon

Health care stocks were slipping late Thursday afternoon, with the NYSE Health Care Index down 1% an PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

UroGen Pharma GAAP EPS of -$1.05 misses by $0.23, revenue of $24.2M beats by $1.07M

* UroGen Pharma press release [https://seekingalpha.com/pr/20193018-urogen-pharma-expands-commercial-portfolio-with-launch-of-zusduri-and-reports-second-quarter] (NASDAQ:URGN [https://seekingalpha.com/symbol/URGN]): Q2 GAAP EPS of -$1.05... Full story

Yahoo Finance • 2 months ago

UroGen Pharma Q2 2025 Earnings Preview

* UroGen Pharma (NASDAQ:URGN [https://seekingalpha.com/symbol/URGN]) is scheduled to announce Q2 earnings results on Thursday, August 7th, before market open. The consensus EPS Estimate is -$0.83 [https://seekingalpha.com/symbol/URGN/ea... Full story

Yahoo Finance • 2 months ago

UROGEN FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors in to Inquire About Their Rights in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UroGenbetween July... Full story

Yahoo Finance • 2 months ago

UroGen's bladder cancer treatment shows promise for home administration

PRINCETON, N.J. - UroGen Pharma Ltd. (NASDAQ:URGN), a pharmaceutical company with an impressive gross profit margin of nearly 90%, announced Monday that a Phase 3b study has demonstrated the feasibility of administering its bladder cancer... Full story

Yahoo Finance • 2 months ago

UROGEN DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds UroGen Pharma (URGN) Investors of the July 28th Deadline and Urges Investors to Inquire About Their Rights in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UroGenbetween July... Full story

Yahoo Finance • 2 months ago

INVESTOR ALERT: Holzer & Holzer, LLC Reminds Investors of July 28, 2025 Lead Plaintiff Deadline in the UroGen Pharma Ltd. (URGN) Class Action – Investors With Significant Losses Encouraged to Contact the Firm

ATLANTA, July 21, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). The lawsuit alleges that Defendants made materially false and/or misleadi... Full story

Yahoo Finance • 2 months ago

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Findings published in the journal of Clinical Genitourinary Cancer show patients remained event-free for a median of two years after achieving complete response with ZUSDURI (mitomycin) intravesical solution. Among the 17 patients who achi... Full story

Yahoo Finance • 2 months ago

UROGEN ALERT: Bragar Eagel & Squire, P.C. Urges Investors in UroGen Pharma (URGN) to Inquire About Their Rights in Class Action Lawsuit

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UroGenbetween July... Full story

Yahoo Finance • 3 months ago

URGN Class Action News: UroGen Pharma Ltd. Investors with Large Losses Should Contact Robbins LLP Before July 28 for Information About Leading the Class Action  

SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and... Full story

Yahoo Finance • 3 months ago

UROGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Against UroGen Pharma Ltd. And Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UroGen Pharma (URGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in UroGenbetween July... Full story

Yahoo Finance • 3 months ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Organon, UroGen and Fortrea and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Organon (OGN), UroGen (URGN), Red Cat (RCAT), or Fortrea (FTRE) To Contact Him Directly To Discuss Their Options If you purchased or... Full story

Yahoo Finance • 3 months ago

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Reckitt Benckiser Group p... Full story

Yahoo Finance • 3 months ago

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J., July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it... Full story

Yahoo Finance • 3 months ago

UroGen Pharma awards special bonuses to executives following FDA approval

UroGen Pharma Ltd. (NASDAQ:URGN), a biopharmaceutical company with a market capitalization of approximately $598 million, disclosed that its board of directors approved one-time special bonuses for three executive officers on June 30, 2025... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - URGN

NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN). Such investors are advised to contact Danielle Peyton a... Full story

Yahoo Finance • 3 months ago

URGN Stock News: Robbins LLP Reminds UroGen Pharma Ltd. Investors of the Pending Lead Plaintiff Deadline in the URGN Class Action – Contact Robbins LLP Before July 28 for Information

SAN DIEGO, June 30, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).  Such investors are advised to contact Danielle Peyton at newacti... Full story

Yahoo Finance • 3 months ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).  Such investors are advised to contact Danielle Peyton at newacti... Full story